N※N

Northern Ireland Veterinary Sector Faces Medicine Crisis Post-Brexit

  //health-fitness.news-articles.net/content/2026/ .. ry-sector-faces-medicine-crisis-post-brexit.html
  Published in Health and Fitness on Friday, March 27th 2026 at 2:51 GMT by BBC
      Locales: UNITED STATES, CANADA

Belfast, Northern Ireland - March 27th, 2026 - Two years after the initial post-Brexit adjustments, Northern Ireland's veterinary sector is facing a deepening crisis regarding the availability and regulation of vital veterinary medicines. The British Veterinary Association (BVA) and the Northern Ireland Veterinary Association (NIVMA) are issuing increasingly urgent pleas for governmental intervention, warning that continued ambiguity threatens animal health and welfare across the region.

The initial concerns, voiced immediately following the UK's departure from the European Union, haven't subsided; they've escalated into tangible shortages and bureaucratic hurdles impacting veterinary practices of all sizes. While the Windsor Framework aimed to ease trade between Great Britain and Northern Ireland, its application to veterinary medicines has proven complex and, for many practitioners, insufficient. The unique position of Northern Ireland - simultaneously part of the UK and aligned with certain EU regulations - has created a regulatory quagmire.

Supply Chain Vulnerabilities Exposed

The core issue revolves around the complex import and licensing procedures now in place for veterinary medicines originating from Great Britain. Previously, these medications flowed freely within the UK. Now, they are subject to customs checks, regulatory compliance hurdles and, increasingly, delays. This has led to intermittent shortages of crucial drugs, including antibiotics, parasiticides, anesthetics, and specialized medications for farm animals. Livestock farmers are particularly vulnerable, with reports of difficulty obtaining necessary treatments for disease outbreaks, potentially impacting food production and animal wellbeing.

Dr. Eleanor Vance, President of the NIVMA, explains: "We are seeing practices regularly spending hours each week navigating the new paperwork and dealing with logistical problems. This administrative burden detracts from valuable time that should be dedicated to animal care. More importantly, the unpredictable supply chain means we sometimes cannot access the medications our patients urgently need."

Licensing Labyrinth and Future Innovations The licensing of veterinary medicines is another significant bottleneck. The Medicines and Healthcare products Regulatory Agency (MHRA) - the UK's regulatory body - is responsible for approving medications. However, the divergence between UK and EU licensing procedures is creating complications. Medicines approved in the EU but not yet licensed in the UK face significant delays in becoming available to Northern Irish vets. This is particularly concerning for newer, innovative treatments that offer improved efficacy or safety profiles. The BVA is advocating for a streamlined process that allows quicker access to approved EU medications, acknowledging the importance of maintaining alignment with international veterinary standards.

"We're not asking for special treatment, we're asking for practical solutions," says Gavin Wright, BVA representative. "Northern Ireland needs a pragmatic approach that allows vets to access safe and effective medicines without unnecessary delays. The current system is unsustainable and puts animal welfare at risk."

Impact on Animal Welfare and Public Health The consequences of these challenges extend beyond inconvenience. Delays in treatment can lead to prolonged suffering for animals, increased morbidity, and even mortality. The limited availability of certain medications also raises concerns about antimicrobial resistance. If vets are unable to prescribe the most appropriate antibiotics, it could contribute to the development of resistant bacteria, posing a threat to both animal and public health.

The situation is particularly acute for specialized veterinary practices, such as those dealing with equine or exotic animals, where the range of available medications is often narrower and supply chains more vulnerable.

Calls for Urgent Action The BVA and NIVMA are demanding the following from the UK government:

• Clear and Concise Guidance: A comprehensive and easily accessible guide outlining the specific import and licensing requirements for veterinary medicines in Northern Ireland.
• Streamlined Processes: Simplification of the administrative procedures for importing and licensing medications, reducing the bureaucratic burden on veterinary practices.
• Supply Chain Resilience: Proactive measures to ensure a stable and reliable supply of veterinary medicines, including contingency plans to address potential disruptions.
• Recognition of EU Approvals: A mechanism for recognizing EU-approved veterinary medicines, allowing faster access to innovative treatments.
• Financial Support: Consideration of financial assistance for veterinary practices to help cover the increased costs associated with the new regulatory requirements.

As the crisis continues, the future of veterinary medicine in Northern Ireland hangs in the balance. Without decisive action from the government, the BVA and NIVMA warn that animal health and welfare will continue to be compromised, jeopardizing the livelihoods of veterinary professionals and the wellbeing of animals across the region.